The British HIV Association national clinical audit 2021: Management of HIV and hepatitis C coinfection.
HIV
audit
coinfection
hepatitis C virus
micro-elimination
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
24
06
2022
accepted:
15
09
2022
medline:
12
4
2023
pubmed:
30
9
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
We aimed to describe clinical policies for the management of people with HIV/hepatitis C virus (HCV) coinfection and to audit routine monitoring and assessment of people with HIV/HCV coinfection attending UK HIV care. This was a clinic survey and retrospective case-note review. HIV clinics in the UK participated in the audit from May to July 2021 by completing an online questionnaire regarding their clinic's policies for the management of people with HIV/HCV coinfection, and by contributing to a case-note review of people living with HIV with detectable HCV RNA who were under the care of their service. Ninety-five clinics participated in the clinic survey; of these, 15 (15.8%) were regional specialist centres, 19 (20.0%) were HIV services with their own coinfection clinics, 40 (42.1%) were HIV services that referred coinfected individuals to a local hepatology service and 20 (21.1%) were HIV services that referred to a regional specialist centre. Eighty-one clinics provided full caseload estimates; of the approximately 3951 people with a history of HIV/HCV coinfection accessing their clinics, only 4.9% were believed to have detectable HCV RNA, 3.15% of whom were already receiving or approved for direct-acting antiviral (DAA) treatment. In total, 29 (30.5%) of the clinics reported an impact of COVID-19 on coinfection care, including delays or reductions in the frequency of services, monitoring, treatment initiation and appointments, and changes to the way that treatment was dispensed. Case-note reviews were provided for 283 people with detectable HCV RNA from 74 clinics (median age 42 years, 74.6% male, 56.2% HCV genotype 1, 22.3% HCV genotype 3). Overall, 56% had not received treatment for HCV, primarily due to lack of engagement in care (54.7%) and/or being uncontactable (16.4%). Our findings show that the small number of people with HIV with detectable HCV RNA in the UK should mean that it is possible to achieve HCV micro-elimination. However, more work is needed to improve engagement in care for those who are untreated for HCV.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-479Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Ireland G, Delpech V, Kirwan P, et al. Prevalence of diagnosed HIV infection among persons with hepatitis C virus infection: England, 2008-2014. HIV Med. 2018;19(10):708-715.
Thornton AC. Viral Hepatitis and HIV Co-Infection in the UK Collaborative HIV Cohort (UK CHIC) Study: UCL. University College London; 2015.
PHE. HIV in the United Kingdom: Towards Zero HIV transmissions by 2030. 2019.
Bhagani S. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Curr Opin HIV AIDS. 2011;6(6):483-490.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
Pol S, Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations”. Liver Int. 2018;38:28-33.
Organization WH. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis. World Health Organization; 2016.
Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-184.
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319-1329.
Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination-a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665-666.
Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Seminars in Liver Disease. Thieme Medical Publishers; 2018.
The Lancet HIV. Microelimination could be a big deal for HCV and HIV services. Lancet HIV. 2018;5(11):e605.
BHIVA. BHIVA calls for accelerated efforts to prevent and cure hepatitis C infection. 2018. http://www.bhiva.org/BHIVA-calls-for-accelerated-efforts-to-prevent-and-cure-hepatitis-C-infection.
Garvey LJ, Cooke GS, Smith C, et al. Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: Progress to HCV microelimination in the United Kingdom? Clin Infect Dis. 2021;72(2):233-238.
Shayan SJ, Nazari R, Kiwanuka F. Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis. Harm Reduct J. 2021;18(1):1-13.
de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in a msterdam; evidence for harm reduction? Addiction. 2013;108(6):1070-1081.
Braun DL, Hampel B, Ledergerber B, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV cohort study. Clin Infect Dis. 2021;73(7):e2194-e2202.
Martinello M, Yee J, Bartlett SR, et al. Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE study. Clin Infect Dis. 2019;71(6):1502-1510.
Smit C, Boyd A, Rijnders BJA, et al. HCV micro-elimination in individuals with HIV in The Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV. 2021;8(2):e96-e105.
Pradat P, Huleux T, Raffi F, et al. Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. AIDS. 2018;32(8):1077-1082.
Simões D, Stengaard AR, Combs L, Raben D. Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European region, march to august 2020. Euro Surveill. 2020;25(47):2001943.
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: the potential role of telehealth, medications for opioid use disorder and minimal demands on patients. Int J Drug Policy. 2022;101:103570.
Preko P, Shongwe S, Abebe A, Vandy A, Aly D, Boraud F. Rapid adaptation of HIV differentiated service delivery program design in response to COVID-19: results from 14 countries in sub-Saharan Africa. AIDS. 2020. http://programme.aids2020.org/Abstract/Abstract/10900.
Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, et al. HIV care in times of the COVID-19 crisis-where are we now in central and Eastern Europe? Int J Infect Dis. 2020;96:311-314.
Ballester-Arnal R, Gil-Llario MD. The virus that changed Spain: impact of COVID-19 on people with HIV. AIDS Behav. 2020;24(8):2253-2257.
Roberson JL, Lagasca AM, Kan VL. Comparison of the hepatitis C continua of care between hepatitis C virus/HIV coinfected and hepatitis C virus mono-infected patients in two treatment eras during 2008-2015. AIDS Res Hum Retrovir. 2018;34(2):148-155.
Zuckerman A, Douglas A, Nwosu S, Choi L, Chastain C. Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era. PLoS One. 2018;13(6):e0199174.
Hawkins C, Grant J, Ammerman LR, et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemother. 2016;71(9):2642-2645.
Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215-223.
Cachay ER, Torriani FJ, Hill L, et al. Hepatitis C knowledge and recent diagnosis affect hepatitis C treatment willingness in persons living with HIV. JAIDS J Acq Immu Def Syndr. 2021;87(1):e159-e166.
England PH. In: Team NH, ed. Hepatitis C: Interventions for Patient Case-Finding and Linkage to Care Evidence Review. PHE Publication; 2019.
Weiss JJ, Aaronson C, Cervantes L, et al. A behavioral intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial. J Hepatol. 2017;66(1 Suplement 1):S490.
Roberts K, Macleod J, Metcalfe C, et al. Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. BMJ. 2020;368:m322.
Horwood J, Clement C, Roberts K, et al. Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (hepatitis C assessment through to treatment) trial. Br J Gen Pract. 2020;70(697):e581-e588.
Harrison GI, Murray K, Gore R, et al. The hepatitis C awareness through to treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019;114(6):1113-1122.
NHS Commissioning Board. Developing Operational Delivery Networks the Way Forward. 2012. https://www.england.nhs.uk/wp-content/uploads/2012/12/develop-odns.pdf.
McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32:151-156.
Paisi M, Crombag N, Burns L, et al. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Health Expect. 2022;25(1):48-60.
Stagg HR, Surey J, Francis M, et al. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. BMC Med. 2019;17(1):1-9.
Jugnarain DV, Halford R, Smith S, Hickman M, Samartsidis P, Foster GR. Role of peer support in a hepatitis C elimination programme. J Viral Hepat. 2022;29(1):43-51.
Magidson JF, Joska JA, Regenauer KS, et al. “Someone who is in this thing that I am suffering from”: the role of peers and other facilitators for task sharing substance use treatment in south African HIV care. Int J Drug Policy. 2019;70:61-69.
Berg RC, Page S, Øgård-Repål A. The effectiveness of peer-support for people living with HIV: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252623.
British HIV Association. Standards of Care for People Living with HIV 2018. British HIV Association; 2018.
Positively UK. National Standards for Peer Support in HIV. 2016. https://positivelyuk.org/wp-content/uploads/2022/06/national_standards_final_web.pdf.
Garvey L, Curtis H, Brook G. The British HIV Association national audit on the management of subjects co-infected with HIV and hepatitis B/C. Int J STD AIDS. 2011;22(3):173-176.